Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Zirconium Cyclosilicate in CKD With or at Risk of Hyperkalemia
CTR20220288Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Feb 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sodium zirconium cyclosilicate in chronic kidney disease (CKD), hyperkalemia, sponsored by AstraZeneca. Started Feb 2022; status: terminated.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
chronic kidney disease (CKD)hyperkalemia
Beyond the preview
Go deeper on CTR20220288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220288.